Literature DB >> 21072821

Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.

Zhipeng Li1, Rong Yang, Jiangning Zhao, Ruirong Yuan, Quanyi Lu, Qingge Li, William Tse.   

Abstract

We report a rare pediatric chronic eosinophilic leukemia (CEL) case of an 8-year-old male whose leukemic cells carried t(1; 5)(q21; q33) chromosomal abnormality. Sequencing analysis confirmed a TPM3-PDGFRB fusion, and the breakpoint was the same as adult patient. Targeted therapy with imatinib induced a rapid hematologic response and reduction of TPM3-PDGFRB transcripts as monitored by reverse transcription real-time PCR (RT-qPCR). We then established an RT-qPCR assay applicable to detection of all possible PDGFRB fusions and also validated this assay in the patient. These data should provide a valuable reference for management of pediatric CEL.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21072821     DOI: 10.1002/pbc.22800

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Proteomic analysis indicates the importance of TPM3 in esophageal squamous cell carcinoma invasion and metastasis.

Authors:  Shao-Bin Yu; Qin Gao; Wen-Wei Lin; Ming-Qiang Kang
Journal:  Mol Med Rep       Date:  2017-01-25       Impact factor: 2.952

2.  Delivery of platelet TPM3 mRNA into breast cancer cells via microvesicles enhances metastasis.

Authors:  Bing Yao; Shuang Qu; Ruifeng Hu; Wen Gao; Shidai Jin; Junyi Ju; Quan Zhao
Journal:  FEBS Open Bio       Date:  2019-11-21       Impact factor: 2.693

3.  Myeloid neoplasm with eosinophilia and rearrangement of platelet-derived growth factor receptor beta gene in children: Two case reports.

Authors:  Shi-Chong Wang; Wen-Yu Yang
Journal:  World J Clin Cases       Date:  2021-01-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.